| Name : Mrs. MAUSUMI DAS (57 /F) | | Date : 26/03/2024 |
|---|-------------------------|----------------------------|
| Address : KOLKATA, KOLKATA, KOLKATA, W | VEST BENGAL, INDIA | |
| Examined by: Dr .JHUMA BAGCHI | | UHID : AMHL.0002320282 |
| Package : MEDIWHEEL - FULL BODY ANNUAL F FEMALE HCK | PLUS CHECK ADVANCE | AHC No: AMHLAH201418 |
| | - Nil Significant | |
| | Skin | |
| For corporate health checkup | - Nil Significant | |
| Shortness of breath | Present medica | tions |
| PRESENT KNOWN ILLNESS | - ROZALET 20 | |
| No history of - Diabetes mellitus, | ANGISPAN | |
| Hypertension | | |
| DyslipidaemiaMedication - regularOthers- RBBB on medication | 1 | tory |
| Others - RBBB on medication | Past medical history | - nil significant |
| | Personal history | |
| NO KNOWN ALLERGY :26/03/2024 | Marital status | - Married |
| | Diet | - Non Vegetarian |
| $\overline{\Lambda}$ | Alcohol | - does not consume alcohol |
| Cardiovascular system | Smoking | - No |
| Breathing difficulty - yes; Exacerbated by - moderate | Chews tobacco | - No |
| exertion | Physical activity | - Mild |
| Respiratory system | Family history | |
| - Nil Significant | Father | - has expired |
| Gastrointestinal system | Mother | - has expired |
| - Nil Significant | Coronary artery | - none |
| Genitourinary system | disease Cancer | - None |
| - Nil Significant | | |
| Gynaec history | PHYSICAL EXAMIN | ATION |
| | 🛃 General | |
| No of Children - 1; Deliveries - LSCS; Menopause - yes | Build | - normal |
| | Height | - 152 |
| Central nervous system | Weight | - 53 |
| - Nil Significant | BMI | - 22.94 |
| Eyes | Pallor | - No |
| Vision - normal with glasses; Glasses - yes | Oedema | - no |
| ENT | Cardiovascular s | ystem |
| - Nil Significant | Heart rate (Per minute) | - 68 |
| Musculoskeletal system | Rhythm | - Regular |
| Spine and joints | | - B.P. Sitting |
| , ····J-···- | | |

UHID : AMHL.0002320282

: 26/03/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH201418

| Systolic(mm of Hg) | - 124 |
|---------------------|---------|
| Diastolic(mm of Hg) | - 80 |
| Heart sounds | - S1S2+ |

Respiratory system

Breath sounds - Normal vesicular breath sounds



Organomegaly - No Tenderness - No

Opthalmology consultation

Opthalmology findings

- PGVA:RE:6/6P LE:6/6P BCVA:RE:N6 LE:N6 OCULAR MOVEMENT:WNL ANT.SEG:WNL ADVICE:*To continue present glass Rx*Detail dilated Funduscopy*Review after 1yr/SOS

Printed By : Benazir Begaum

: 26/03/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH201418

| COMPLETE HAEMOGRAM PROFILE | | | | | | | |
|--|--------|------------------|------------|--|--|--|--|
| Test Name | Result | Unit Level | Range | | | | |
| Hemoglobin | 12.1 | g/dl 📃 🔍 | 12.0-15.0 | | | | |
| RBC COUNT | 3.96 | Million/ | 3.8-4.8 | | | | |
| Hematocrit - Hct: | 37.5 | % | 36-46 | | | | |
| MCV | 94.9 | fl 🛛 🔍 | 83-101 | | | | |
| MCH | 30.5 | pg 📃 | 27-32 | | | | |
| MCHC | 32.2 | % | 31.5-34.5 | | | | |
| RDW | 14.2 * | % | 11.8-14.0 | | | | |
| WBC Count | 4800 | /cu mm 🔍 | 4000-10000 | | | | |
| Platelet Count | 0.92 * | lacs/cu ● mm | 1.5-4.0 | | | | |
| Neutrophils | 60 | % | 40-80 | | | | |
| Lymphocytes | 33 | % | 20-40 | | | | |
| Monocytes | 06 | % | 2-10 | | | | |
| Eosinophils | 01 | % | 01-06 | | | | |
| Basophils | 00 | % | 0-0 | | | | |
| RBC: | Normoc | ytic Normochro | omic cells | | | | |
| Platelets: | Reduce | d on Smear. | | | | | |
| ERYTHROCYTE SEDIMENTATION RATE (ESR) | 14 | mm/1st ● hr | 0-20 | | | | |

URINE ROUTINE AND MICROSCOPY

| Test Name | Result Un | it Level | Range | |
|------------------|---------------|----------|-------|--|
| Volume: | 40 m | ηL | | |
| Colour: | Pale Straw | | | |
| Appearance | Slightly Turk | bid | | |
| Specific Gravity | 1.020 | | | |
| pH: | 6.0 | | | |
| Albumin: | Not Detecte | d | | |
| Glucose | Not Detecte | d | | |
| Ketone: | Not Detected | | | |
| Bile Pigments | Not Detected | | | |
| RBC | Nil /r | npf | | |
| Pus Cells | Occasionalh | ıpf | | |
| Epithelial Cells | Occasional | ıpf | | |

Within Normal Range

| | Casts: | Not Fou | ind | | |
|-----------------|-------------------------------------|----------|-----------------|-------|---------|
| 9 5.0 | Crystals: | Not Fou | ind | | |
| 3 | URINE SUGAR - POST (QUALITATIVE) | PRAN | DIAL | | |
| | Test Name | Result | Unit | Level | Range |
| 1 | URINE GLUCOSE(POST PRANDIAL) | Nil | | | |
| 4.5 | URINE SUGAR- FASTI | NG(QU | ΔΙ ΙΤΔ ΄ | | |
| 4.0 | Test Name | Result | | Level | Range |
| 10000 D | URINE GLUCOSE(FASTING) | Nil | | | |
| | BLOOD GROUPING A | ND TYP | PING (A | | ND RH) |
| | Test Name | Result | Unit | | Range |
| | ABO Group: | В | | | |
| | Rh (D) Type: | NEGAT | IVE | | |
| | LIVER FUNCTION TES | ST (PAC | KAGE |) | |
| s | Test Name | Result | Unit | • | Range |
| 5 | ALT(SGPT) - SERUM | 32 | U/L | • | 0-35 |
| | ALBUMIN - SERUM | 4.6 | g/dL | • | 3.5-5.1 |
| | ALKALINE PHOSPHATASE - SERUM | 92 | U/L | • | 33-98 |
|) | AST (SGOT) - SERUM | 25 | U/L | • | 0-35 |
| | BILIRUBIN TOTAL - SERUM | 0.9 | mg/dl | • | 0.3-1.2 |
| | LIPID PROFILE TEST | | GE) | | |
| | Test Name | Result | Unit | Level | Range |
| | CHOLESTEROL - SERUM | 175 | mg/dl | - | 0-200 |
| | CREATININE - SERUM | I | | | |
| | Test Name | Result | Unit | Level | Range |
| | CREATININE - SERUM | 0.7 | mg/dl | • | 0.6-1.1 |
| | LIVER FUNCTION TES | ST (PAC | KAGE |) | |
| | Test Name | Result | | | Range |
| Borderlin | ne High/Low 😑 Out | of Range |) | | |

: 26/03/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH201418

| GGTP: GAMMA GLUTAMYL TRANSPEPTIDASE - SERUM | 25 | U/L | • | 0-38 | TOTAL T3: TRI IODOTHYRONINE - SERUM | 1.05 | ng/ml | | 0.87-1.78 |
|---|--|--|---------------------------------------|---|--|--|---------------------------------------|--------------------|---------------------------------------|
| GLUCOSE - PLASMA | (FASTI | NG) | | | TOTAL T4: THYROXINE - SERUM | 10.79 | µg/dL | • | 5.48-14.28 |
| Test Name | Result | • | Level | Range | INTROAINE - SERUM | | | | |
| GLUCOSE - PLASMA | 94 | ma/d | L | 70-99 | LIPID PROFILE TEST | (PACKA | AGE) | | |
| (FASTING) | 01 | | | 1000 | Test Name | Result | | Level | Range |
| | | | | | TRIGLYCERIDES - | 85 | mg/dl | L | 0-150 |
| GLUCOSE - PLASMA | • | | | _ | SERUM | | | | |
| Test Name | | | | Range | | UT2 TA | | <u></u> | |
| GLUCOSE - PLASMA | 117 | mg/d | L | 70-140 | THYROID PROFILE - I | • | | | D |
| (POST PRANDIAL) | | | | | Test Name | Result | | | |
| HBA1C (GLYCOSYLA | TED | | | | TSH: THYROID STIMULATING | 1.44 | µIU/n | nL 🛡 | 0.38-5.33 |
| HAEMOGLOBIN)-WHO | | OOD | | | HORMONE - SERUM | | | | |
| , Test Name | Result | | Level | Range | | | | | |
| HBA1C | 4.9 | % | ٠ | Nondiadetic: 4 | URIC ACID - SERUM | | | | |
| (GLYCOSYLATED | | | | - 5.6 % | Test Name | Result | Unit | Level | Range |
| HAEMOGLOBIN)-WHO LE BLOOD | | | | Prediabetics : 5.7 - 6.4% | URIC ACID - SERUM | 4.0 | mg/dl | L | 2.4-5.7 |
| | | | | Diabetes : | | | | ·\ | |
| | | | | >/= 6.5% | LIVER FUNCTION TES | • | | | _ |
| | | | | ADA Theraputic goal | Test Name | | | - | Range |
| | | | | : <7% | BILIRUBIN | 0.2 | mg/dl | | 0.0-0.2 |
| | | | | . <1% | CONJUGATED (DIRECT) - SERUM | | | | |
| LIPID PROFILE TEST | (PACKA | AGE) | | . <1% | (DIRECT) - SERUM | | | | |
| LIPID PROFILE TEST Test Name | (PACKA Result | • | Level | Range | | NITROGI | EN) | | |
| Test Name HDL CHOLESTEROL - | • | • | | | (DIRECT) - SERUM | NITROGI Result | | Level | Range |
| Test Name | Result | Unit | | Range | (DIRECT) - SERUM | | | | Range 7.0-18.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL | Result | Unit | L | Range | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) | Result 11.4 | Unit mg/dl | L • | |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM | Result 87 * 84 | Unit mg/d mg/d | L • | Range 30-70 0-100 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES | Result 11.4 ST (PAC | Unit mg/dl | L ● | 7.0-18.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - | Result 87 * 84 | Unit mg/d mg/d | L | Range 30-70 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name | Result 11.4 ST (PAC Result | Unit mg/dl | L ● | 7.0-18.0 Range |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM | Result 87 * 84 | Unit mg/d mg/d | L • | Range 30-70 0-100 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES | Result 11.4 ST (PAC | Unit mg/dl | L ● | 7.0-18.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) | Result 87 * 84 4 | Unit mg/d mg/d | L • | Range 30-70 0-100 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name | Result 11.4 ST (PAC Result 1.9 | Unit mg/dl | L ● | 7.0-18.0 Range |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - | Result 87 * 84 4 | Unit mg/d mg/d mg/d | L • L • | Range 30-70 0-100 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO | Result 11.4 ST (PAC Result 1.9 | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) | Result 87 * 84 4 ST (PAC | Unit mg/d mg/d mg/d | L • L • | Range 30-70 0-100 0-35 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA | Result 11.4 ST (PAC Result 1.9 TIO | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range 1.0-2.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - | Result 87 * 84 4 ST (PAC Result | Unit mg/d mg/d mg/d KAGE Unit | L • L • | Range 30-70 0-100 0-35 Range | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE | Result 11.4 ST (PAC Result 1.9 TIO Result | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range 1.0-2.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: (CALCULATED) - | Result 87 * 84 4 ST (PAC Result 7.0 | Unit mg/d mg/d mg/d KAGE Unit g/dL | L • L • | Range 30-70 0-100 0-35 Range 6.4-8.3 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE | Result 11.4 ST (PAC Result 1.9 TIO Result 15.3 | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range 1.0-2.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: | Result 87 * 84 4 ST (PAC Result 7.0 | Unit mg/d mg/d mg/d KAGE Unit g/dL | L • L • | Range 30-70 0-100 0-35 Range 6.4-8.3 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE RATIO PAP SMEAR /CERVICAL Ref No: | Result 11.4 ST (PAC Result 1.9 TIO Result 15.3 | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range 1.0-2.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: (CALCULATED) - SERUM | Result 87 * 84 4 ST (PAC Result 7.0 2.4 | Unit mg/d mg/d mg/d KAGE Unit g/dL g/dL | L • L • E) Level | Range 30-70 0-100 0-35 Range 6.4-8.3 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE RATIO PAP SMEAR /CERVICAL Ref No: AG01.C2402543 | Result 11.4 ST (PAC Result 1.9 TIO Result 15.3 | Unit mg/dl KAGE Unit | L • .) Level | 7.0-18.0 Range 1.0-2.0 |
| Test Name HDL CHOLESTEROL - SERUM LDL CHOLESTEROL -SERUM VLDL CHOLESTEROL - SERUM (Calculated) LIVER FUNCTION TES Test Name PROTEIN TOTAL - SERUM GLOBULIN: (CALCULATED) - | Result 87 * 84 4 ST (PAC Result 7.0 2.4 (T3,T4 / | Unit mg/d mg/d mg/d KAGE Unit g/dL g/dL | L • L • E) Level • SH) | Range 30-70 0-100 0-35 Range 6.4-8.3 | (DIRECT) - SERUM BUN (BLOOD UREA N Test Name BUN (BLOOD UREA NITROGEN) LIVER FUNCTION TES Test Name A/G - RATIO BUN/CREATININE RA Test Name BUN/CREATININE RATIO PAP SMEAR /CERVICAL Ref No: | Result 11.4 ST (PAC Result 1.9 TIO Result 15.3 L SMEAF | Unit mg/dl KAGE Unit Unit | L • | 7.0-18.0 Range 1.0-2.0 Range |

: 26/03/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No ; AMHLAH201418

SPECIMEN ADEQUACY: Satisfactory for evaluation INTERPRETATION/RESULT: Negative for intraepithelial lesion or malignancy, cellular changes associated with Atrophy.

ECG

SINUS RHYTHM. LOW VOLTAGE "QRS" & T WAVES.

TREADMILL TEST / STRESS TEST

STRESS TEST IS NEGATIVE FOR PROVOCABLE MYOCARDIAL ISCHAEMIA.

ULTRASOUND SCREENING WHOLE ABDOMEN

* No significant abnormality detected.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.]

Within Normal Range

X-RAY CHEST PA

* Chest skiagram does not reveal any significant abnormality.

X-RAY MAMMOGRAPHY BILATERAL (MHC)

Heterogeneously dense bilateral breast which may obscure small masses- BIRADS 0

Bilateral breasts benign morphology calcifications

Advise further evaluation by sonography

bIRADS Category:

- 0. Requires additional evaluation
- 1. Negative

Borderline High/Low

Out of Range

- 2. Benign findings
- 3. Intermediate
- 4. Suspicious malignancy
- 5. Highly suggestive of malignancy
- 6: (Histo-pathologically proven)

---END OF THE REPORT---

Dr. SUDESHNA MALAKAR MD, DNB, MNAMS, FRCR CONSULTANT RADIOLOGIST Reg. No ?" 70658 (WBMC) Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No ; AMHLAH201418

Printed By :

Dr.JHUMA BAGCHI

AHC Physician / Consultant Internal Medicine

Date

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases. Name : Mrs. MAUSUMI DAS (57 /F)

: 26/03/2024

Date

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCE FEMALE HCK AHC No : AMHLAH201418

| AICVD RISK SCORE REPORT | | | | | | | |
|---|---|---|--|--|--|--|--|
| RISK STATUS YOUR SCORE ACCEPTABLE SCORE | | | | | | | |
| Low Risk | 6 | 7 | | | | | |

Your cardiovascular disease risk in the next 10 years is within the Normal limits for your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence -based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with **medications** for high blood pressure, diabetes, or dyslipidemia, if advised by your physician. Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- Follow your physician's advice regarding follow up tests, consults and annual health assessment

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician 's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side .
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical AI Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515